• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CHM

CHIMERIC THERAPEUTICS LIMITED - News & Media

12.5% ! 0.4¢
Market Cap $11.37M  !
Healthcare Biotechnology
Add to My Watchlist

Chimeric Therapeutics Limited is an Australia-based clinical-stage cell therapy company,... Chimeric Therapeutics Limited is an Australia-based clinical-stage cell therapy company, focused on the discovery, development, and commercialization of cell therapies for patients with cancer. Its diversified portfolio includes first-in-class autologous CAR T cell therapies and allogeneic natural killer (NK) cell therapies. Its assets are being developed across multiple different disease areas in oncology with four clinical stage programs. Its pipeline includes CHM CDH17, CHM CLTX and CHM CORE NK platform. CHM CDH17 is a third-generation CDH17 CAR T, which is in phase I/II clinical trial in gastrointestinal and neuroendocrine tumors. CHM CORE-NK is a clinically validated NK cell platform in phase IB clinical trials investigating CORE-NK in combination regimens. CHM CLTX is a novel CAR-T therapy developed for the treatment of patients with solid tumors. CLTX CAR T is in phase IB clinical trial in recurrent/progressive glioblastoma. It is also building a Cell therapy portfolio.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Articles & Videos

Chimeric clocks $4.17M R&D tax rebate from Canberra

Chimeric Therapeutics (ASX:CHM) has confirmed its receipt of a $4.17M tax rebate from Canberra for R&D activities.

28 Nov 2024 11:45 (AEDT)

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Chimeric Therapeutics (ASX:CHM) has reported one leukaemia patient has shown a complete response in its latest drug trial.

07 Oct 2024 11:17 (AEDT)

Chimeric Therapeutics treats first patient in Advent-AML phase 1B clinical trial

Chimeric Therapeutics (ASX:CHM) has treated the first patient in its Advent-AML phase 1B clinical trial at The University of Texas MD Anderson Cancer Center.

08 Feb 2024 13:19 (AEDT)

Chimeric Therapeutics announces positive preclinical data for CHM 1301

Chimeric Therapeutics (ASX:CHM) has announced positive in vitro data for CHM 1301, the company's next-generation CLTX CAR NK cell therapy program.

23 Nov 2023 12:53 (AEDT)

Chimeric Therapeutics to raise $10m through entitlement offer

Chimeric Therapeutics (ASX:CHM) has announced it will conduct an equity raising through a two-for-three entitlement offer of new shares, with the goal of raising up to $10 million.

25 Oct 2023 13:11 (AEDT)

Chimeric Therapeutics (ASX:CHM) completes dose escalation in phase 1A brain cancer trial

Chimeric Therapeutics (ASX:CHM) has treated the third patient participating in its phase 1A dose escalation study at the City of Hope Hospital in California.

29 Aug 2023 14:54 (AEST)



Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
0.4¢ 		Change
-0.001(12.5%) 		Mkt cap ! $11.37M
Open High Low Value Volume
0.3¢ 0.4¢ 0.3¢ $10.43K 3.475M

Buyers (Bids)

No. Vol. Price($)
73 70312742 0.3¢
 

Sellers (Offers)

Price($) Vol. No.
0.4¢ 84897305 25
View Market Depth
Last trade - 10.14am 31/07/2025 (20 minute delay) ?
Last
0.4¢ 		  Change
-0.001 ( 16.7 %)
Open High Low Volume
0.4¢ 0.4¢ 0.3¢ 568204
Last updated 12.29pm 31/07/2025 ?
CHM (ASX) Chart

Top Stories

Traders watch with interest as St George Mining reveals REE hit

St George Mining (ASX:SGQ) has revealed it’s hit what it reported as high grade rare earths outside of its existing Mineral Resource Estimate (MRE) boundary, causing the share price to jump 1.2% in morning trade @ implying investors are watching closely but not quite jumping in ye...
Metal Hawk shares sink -50% as gold drill results disappoint Spare a thought for Metal Hawk (ASX:MHK) shareholders on Thursday: the company’s latest RC gold drilling results at its Thylacine project have been dismissed as a duster by the market. Shares in MHK were down an eye-watering -50% in the first hour of trades as investors and trader...
Sun Silver unveils Maverick Springs assay results Sun Silver (ASX:SS1) has reported antimony assay results from its ongoing re-assay program at its Maverick Springs Silver-Gold Project in Nevada, USA.The latest assays from historical drillhole MR103 returned a broad intercept of 59 metres including antimony grades of 7.8%. A second hole, MR092, ...
Investors shrug as Wildcat's latest lithium drill hits fail to excite Wildcat Resources (ASX:WC8) has posted a diamond drill assay of 110m @ 1.2% lithium oxide from 193m depth above the company’s Leia Pegmatite target @ but it hasn’t been enough to cause excitement. The market had collectively shrugged heading into the second hour of...
HotCopper Trends: Final day of quarterlies; Larvotto FID & more Welcome to HotCopper Trends for Thursday 31st of July @ the last day ahead of Washington’s apparent move to un-pause sweeping tariffs. But that’s neither here nor there. (Nor is the fact that this is the last time we should have to deal with a slog of quarterlies, ...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.